Current stock page

Stock Analysis

Glaukos Corporation (GKOS) Stock Analysis

Glaukos Corporation (GKOS) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

GKOS Stock Analysis Summary

Glaukos Corporation (GKOS) currently has an AIQ Score of 65/100, indicating a bullish setup. Momentum is the strongest factor at 90/100. Value is the weakest current factor at 30/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 18, 2026 · Market-close data

GKOS at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$233.08
AIQ Score65/100
Overall ViewBullish
Technical Analysis ConsensusStrong Buy
Market Cap$14.52B
P/E Ratio (TTM)-82.74
Forward P/E—
EPS (Q3 FY2026)$0.03
Revenue (Q3 FY2026)$211.03M
Dividend Yield (TTM)0.00%
Beta1.06
Volume1.13M
52-week range$87.32-$255.19
RSI 1468.68
50-Day SMA$184.62
200-Day SMA$147.26
Analyst Price Target$234.00
Next EarningsFeb 16, 2027
As of Nov 18, 2026 · Market close

GKOSGlaukos Corporation

Healthcare / Medical - Devices

Leader

Strong Relative Position

BullishEdge 8/10
$233.08−$10.17 (−4.18%)

Latest quote

  • Momentum
    90
  • Value
    30
  • Quality
    64
  • Risk resilience
    57
  • Sentiment
    —
algovestiq.comScore data as of Nov 18, 2026

GKOS Stock Analysis Summary

Glaukos Corporation (GKOS) currently has an AIQ Score of 65/100, indicating a bullish setup. Momentum is the strongest factor at 90/100. Value is the weakest current factor at 30/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 18, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, GKOS has AIQ Score of 65/100 with Momentum base of 90/100 and fading Value at 30/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (90/100) leads while Value (30/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -4.18% stock move · GKOS classified in Medical - Devices.

Current Evidence

BullishGKOS is in a bullish AIQ regime; Momentum is the strongest visible factor at 90/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is GKOS Bullish or Bearish Right Now?

GKOS currently has a bullish overall setup. Momentum is the strongest factor at 90/100, while Value is weakest at 30/100. The current evidence suggests a constructive setup.

Bull Case
  • - Momentum is constructive at 90/100.
  • - Price is +33.10% above its 50-day SMA.
  • - Analyst target implies +0.39% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (35 vs 5).
Bear Case
  • - Value is the current constraint at 30/100.

Current Consensus

GKOS's Technical Analysis Consensus is currently Strong Buy, with 35 buy, 6 neutral, and 5 sell votes. GKOS's 14-day RSI is 68.68, which places the stock in a constructive momentum range. GKOS's beta is 1.06, indicating market sensitivity broadly in line with the market.

Signal Confidence
High agreement

What Changed in GKOS?

The largest recent change in GKOS is Momentum moving down by 2.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
-1.0
Momentum
-2.0
Quality
+0.0
Risk
+1.0

What Would Change the GKOS Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

GKOS Decision Framework

Public evidence layers, setup checks, and risk context for Glaukos Corporation.

Glaukos Corporation (GKOS) Stock Analysis

Glaukos Corporation has an AIQ Score of 65/100 in a Bullish regime. Momentum is strongest at 90/100. Beta is 1.06, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextGKOS is in a Bullish AIQ regime with score 65/100.
Signal ConflictThe primary conflict is that momentum leads at 90/100 while value lags at 30/100.
Factor EvidenceMomentum 90/100 · Value 30/100 · Quality 64/100 · Risk 57/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 90/100.

TimingPass

Momentum is 90/100 and RSI (14) is 68.7.

Regime fitPass

GKOS is in a Bullish regime at 65/100.

Risk controlWait

Risk factor is 57/100 with beta 1.06 and annual volatility 61.36%.

ConflictWait

Current conflict: momentum leads at 90/100 while value lags at 30/100.

AIQ Score
65/100
Price
$233.08
Beta
1.06
RSI (14)
68.7

GKOS Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

GKOS Fundamentals

GKOS valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$211.03M
Net income
$2.02M
Free cash flow
$36.49M
View full GKOS fundamental analysis

GKOS Technical Analysis

GKOS technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
68.68
Price vs SMA-50
+33.10%
View full GKOS technical analysis

GKOS Stock Catalysts

Track GKOS earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 16, 2027
Analyst target
$234.00
News items
5
View GKOS earnings and stock catalysts

GKOS Dividend Analysis

GKOS dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View GKOS dividend history and analysis

GKOS Financial Data

GKOS revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$211.03M
EPS
$0.03
Periods
8
View GKOS financials

GKOS Risk Analysis

GKOS volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.06
Risk score
57/100
1Y volatility
61.36%
View GKOS risk analysis

GKOS Stock News

GKOS stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 18, 2026
Sentiment
—
Read GKOS stock news

GKOS vs Medical - Devices Peers

Current peer cohort: GKOS · HAE · IRTC · ITGR · LIVN. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
GKOS
Current stock
65/10030/10090/10057/1001.8361.36%Current
HAE
Haemonetics Corporation
77/10060/10091/10067/1001.3541.04%GKOS vs HAE
IRTC
iRhythm Technologies, Inc.
44/10043/10034/10044/100-0.9154.02%GKOS vs IRTC
ITGR
Integer Holdings Corporation
——85/10080/1002.0231.24%GKOS vs ITGR
LIVN
LivaNova PLC
71/10060/10083/10071/1001.3839.16%GKOS vs LIVN
Pairwise Compare links: HAE · IRTC · ITGR · LIVNGKOS vs HAEGKOS vs IRTCGKOS vs ITGRGKOS vs LIVNCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 18, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 18, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a GKOS stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for GKOS: historical return with reinvested dividends, dollar-cost averaging (DCA) backtest and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 19, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-82.74
As of Nov 18, 2026
Revenue growth
58.03%
Gross margin
81.13%
Current debt / equity
0.14
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$211.03M
Quarter net income
$2.02M
Quarter free cash flow
$36.49M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Bullish
RSI 14
68.68
MACD
19.13

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
57/100
Beta
1.06
Annual volatility
61.36%
Max drawdown
-28.39%

GKOS Stock FAQ

What is GKOS stock price today?

Glaukos Corporation's current stock price is $233.08. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is GKOS bullish or bearish right now?

GKOS's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is GKOS's market cap?

GKOS's market cap is $14.52B based on the latest completed market-close snapshot from Nov 18, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is GKOS's current P/E ratio?

GKOS's current P/E ratio is -82.74 based on the latest completed market-close snapshot from Nov 18, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is GKOS's RSI?

GKOS's 14-day RSI is 68.68 based on the latest completed market-close snapshot from Nov 18, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is GKOS above its 50-day and 200-day moving averages?

GKOS is 33.10% from its 50-day SMA and 66.86% from its 200-day SMA based on the latest completed market-close snapshot from Nov 18, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is GKOS's next earnings date?

GKOS's next earnings date is currently listed as Feb 16, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does GKOS pay a dividend?

GKOS's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 18, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.